Rheumatoid arthritis is an
autoimmune disease that is characterized by chronic
inflammation and destruction of joints.
Netrin-1, a chemorepulsant,
laminin-like matrix
protein, promotes
inflammation by preventing macrophage egress from inflamed sites and is required for osteoclast differentiation. We asked whether blockade of
Netrin-1 or its receptors [Unc5b and DCC (deleted in
colorectal carcinoma)] may be useful therapeutic targets for treatment of inflammatory
arthritis.
Arthritis was induced in 8-wk-old C57Bl/6 mice by
intraperitoneal injection of K/BxN serum. Murine
monoclonal antibodies against
Netrin-1, Unc5b, or DCC (10 µg/mouse) were injected weekly for 4 wk (n = 10). Paw swelling and thickness were assessed and following
euthanasia 2-4 wk after serum transfer, paws were prepared for micro-computed tomography and histology. Paw
inflammation was maximal 2 wk after injection. Anti-Netrin-1 or anti-Unc5b, but not anti-DCC,
antibodies significantly reduced paw
inflammation (clinical score: 9.8 ± 0.8, 10.4 ± 0.9, and 13.5 ± 0.5, respectively vs 16 ± 0 for control; P < 0.001). Micro-computed tomography showed bony erosions in untreated or anti-DCC-treated mice, whereas there were no erosions in anti-
Netrin-1/anti-Unc5b-treated-animals.
Tartrate-resistant acid phosphatase staining demonstrated a marked decrease in osteoclasts in anti-
Netrin-1/anti-Unc5b-treated animals. Immunofluorescence staining revealed a decrease in
cathepsin K+ and CD68+ cells in anti-
Netrin-1/anti-Unc5b-treated animals. Blockade of
Netrin-1/Unc5b by
monoclonal antibodies prevents bone destruction and reduces the severity of K/BxN serum transfer-induced
arthritis.
Netrin-1 may be a novel therapeutic target for treatment of inflammatory bone destruction.-Mediero, A., Wilder, T., Ramkhelawon, B., Moore, K. J., Cronstein, B. N.
Netrin-1 and its receptor Unc5b are novel targets for the treatment of inflammatory
arthritis.